Penumbra's thrombectomy growth and new products show promise, but high valuation at 7x 2025 revenue tempers appeal for GARP investors. Read more on PEN stock here.
Hosted on MSN1mon
Penumbra’s (NYSE:PEN) Q4 Sales Beat EstimatesMedical device company Penumbra (NYSE:PEN ... and technological advancements like minimally invasive procedures and connected devices that improve patient monitoring and outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback